Pfizer: High Yield, High Risk? What Investors Need to Know

Shares of Pfizer (PFE) have fallen over 50% from their late 2021 highs, pushing the dividend yield to a historically high 6.9%. This is significantly higher than the S&P 500's 1.1% yield and the average pharmaceutical stock's 1.5% yield.

The yield spike reflects investor concerns about Pfizer's growth prospects. The company faces several major patent expirations on blockbuster drugs, which typically leads to revenue declines when generic competition enters.

Adding to the pressure, Pfizer had to drop a GLP-1 weight-loss drug it was developing in early 2025, putting it behind competitors in the high-growth obesity market. The dividend payout ratio has also climbed above 130%, raising questions about dividend sustainability.

Despite these headwinds, Pfizer has a long history of navigating patent cliffs and drug development cycles. Management has stated that protecting the dividend is a key priority, and cash flows still cover the payment.

For income-focused investors, Pfizer's 6.9% yield is undeniably attractive, especially in a low-yield environment. However, the high payout ratio and patent cliff risks mean the dividend could be cut if earnings decline further.

The failed GLP-1 drug is a significant setback, as the weight-loss market is one of the fastest-growing in pharma. Pfizer's quick acquisition of a promising weight-loss candidate shows it's trying to catch up, but it remains behind competitors like Novo Nordisk and Eli Lilly.

Pfizer's strong history and pipeline of other drugs provide some cushion, but the next few years will be critical. If new drugs fail to offset patent losses, the stock could remain under pressure.

For aggressive income investors willing to accept risk, the high yield may compensate for potential volatility. Conservative investors should probably wait for clearer signs of a turnaround.